These results could mean some patients may respond adequately to FOLFOX and can ...
Described as one of the largest rounds in Germany, the funding will power pipeli...
Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and curr...
In the latest edition of STAT's Health Tech newsletter: Nuance's mysterious pric...
A study of thousands of people who were prescribed GLP-based drugs like Ozempic ...
Despite pressure from Congress and advocates, CMS isn’t changing its coverage pl...
As the biotech bash BIO 2023 opens tomorrow, industry leaders are bracing for to...
“I believe we are curing the cancer by using these best drugs early,” said the l...
#ASCO23 A brain cancer that usually strikes in early middle age was slowed down ...
#ASCO23 In a study, ovarian cancer patients treated with Elahere lived for a med...
#ASCO23 A “twinning program” between a San Diego and Tijuana hospital reduced su...
Algorithms that adjust for race raise the threshold for diagnosing a problem in ...
Carbon-based stimuli-responsive nanomaterials are gaining much attention due to ...
Credit: Vall d’Hebron Institute of Oncology (VHIO). Presented today by VHIO’s ...
LOS ANGELES and PORTLAND, Ore. — A Phase 3 trial has demonstrated that patients ...
In a bid to combat respiratory syncytial virus (RSV) infections in older adults,...
